International Flavors & Fragrances (IFF) - FREE Research Report

Mirzayantz Nicolas who is Group President Fragrance at International Flavors & Fragrances sold 3,000 shares at $85.00 on Nov. 6, 2013. Following this transaction, the Group President Fragrance owned 70,439 shares meaning that the stake was reduced by 4.09% with the 3,000 share transaction.

The shares most recently traded at $85.88, up $0.88, or 1.02% since the insider transaction. Historical insider transactions for International Flavors & Fragrances go as follows:

  • 12-Week # shares sold: 5,460
  • 24-Week # shares sold: 18,094

The average volume for International Flavors & Fragrances has been 262,800 shares per day over the past 30 days. International Flavors & Fragrances has a market cap of $6.9 billion and is part of the basic materials sector and chemicals industry. Shares are up 26.57% year to date as of the close of trading on Wednesday.

International Flavors & Fragrances Inc., together with its subsidiaries, creates, manufactures, and supplies flavor and fragrance products worldwide. The company operates in two segments, Flavors and Fragrances. The stock currently has a dividend yield of 1.85%. The company has a P/E ratio of 19.3. Currently there are 6 analysts that rate International Flavors & Fragrances a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IFF - FREE

TheStreet Quant Ratings rates International Flavors & Fragrances as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full International Flavors & Fragrances Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Regeneron Pharmaceuticals Ready to Make All-Time Highs

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

If It's Not Earnings News, It's Amazon Competition: Jim Cramer's Best Blog

Electronic Arts, Activision Blizzard and Take-Two Interactive: 'Mad Money' Lightning Round